Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Medicare Part D Prior Auth Policy U…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    2026 Medicare Part D Prior Authorization Requirements (selected drugs)

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Portion of a HealthPartners policy listing Medicare Part D prior authorization requirements for specific specialty and pharmacy drugs, including clinical prerequisites, exclusions, prescriber and coverage duration rules for affected products.

    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Prior Authorization Requirements (selected drugs)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with required diagnostic documentation and evidence of prerequisite therapy or specialist consultation as specified for the requested product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Jan 2026effective date
    12 monthstypical coverage duration (many products)
    6 monthscommon initial duration
    Pending CMS Reviewrequired medical information status
    20+distinct products listed

    Drug-specific Coverage Criteria

    Abiraterone (250 mg, 500 mg)

    Covered when ALL of the following are met:

    Abiraterone initial coverage: Patient has a diagnosis of metastatic high-risk castration-sensitive prostate cancer (mCSPC) OR metastatic castration-resistant prostate cancer (mCRPC); patient does not have an FDA‑labeled limitation of use or contraindication to therapy; dose limited to FDA‑labeled dosing guidelines; if 500 mg tablet requested, provide rationale why 250 mg tablet cannot be used

    Coverage duration: six months

    Actemra (all formulations)

    Covered when ANY of the following indications are met:

    Actemra indications: Diagnosis of one of: (1) rheumatoid arthritis with medical contraindication or inadequate response to at least two preferred drugs; (2) polyarticular juvenile idiopathic arthritis with medical contraindication or inadequate response to at least two preferred drugs; (3) giant cell arteritis with medical contraindication or inadequate response to at least one preferred drug; (4) systemic juvenile idiopathic arthritis; (5) systemic sclerosis‑associated ILD with inadequate response or contraindication to mycophenolate for early diffuse SSc with ILD and early evidence of ILD progression
    Policy Summary
    PayerHealthPartners
    Policy2026 Medicare Part D Prior Authorization Requirements (selected drugs)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Next Review Date
    Key ActionObtain prior authorization with required diagnostic documentation and evidence of prerequisite therapy or specialist consultation as specified for the requested product.
    SourceLink
    On This Page
    Drug-specific Coverage CriteriaInitial Authorization / Start-of-Therapy CriteriaRenewal / Ongoing Therapy CriteriaRequired Prior / Alternative Therapy (Step) RulesIndex and Code ListingsActions, Documentation & Denial Risks for ProvidersQuantity, Duration and Refill LimitsWhere Therapy is Administered / Coverage SettingBiosimilar Preferences and RequirementsClinical Thresholds and Key Numeric CriteriaPolicy Background

    May not be used concurrently with other biologic therapies; prescriber is or in consultation with rheumatologist or pulmonologist; coverage duration 12 months

    Adbry

    Covered when ALL of the following are met:

    Adbry initial criteria: Diagnosis of an FDA‑approved indication not excluded from Part D (e.g., moderate‑to‑severe atopic dermatitis); for atopic dermatitis: ≥10% BSA or involvement of face/neck/hands/feet/genitals/intertriginous areas, intractable pruritus or significant skin breakdown, and inadequate response or contraindication to one prescription‑strength topical corticosteroid or one topical calcineurin inhibitor (tacrolimus or pimecrolimus); may not be used concurrently with another monoclonal antibody therapy; prescriber is or in consultation with allergist, immunologist, or dermatologist

    Coverage duration 12 months

    Adbry renewal: Provider attests treatment goals have been met

    Renewal coverage 12 months

    Adempas

    Covered when ALL of the following are met:

    Adempas initial criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for Group 1 PAH: diagnosis confirmed by right heart catheterization with mean PAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; for WHO Group 4 CTEPH: WHO FC II–IV symptoms and either inoperable disease, not a surgical candidate, or persistent/recurrent disease after surgery; avoid concurrent use with nitrates, nitric oxide donors, PDE inhibitors, or non‑specific PDE inhibitors; prescriber is or in consultation with cardiologist or pulmonologist

    Coverage duration 12 months

    Alpha-1 antitrypsin augmentation

    Covered when ALL of the following are met:

    AAT augmentation initial criteria: Diagnosis of alpha‑1 antitrypsin deficiency with clinically evident emphysema; pretreatment serum AAT level <11 micromoles/L (or <80 mg/dL by radial immunodiffusion or <57 mg/dL by nephelometry); patient will continue conventional emphysema treatment (e.g., bronchodilators); dose limited to FDA‑labeled dosing

    Renewal: seen within past 12 months and positive response; coverage duration 12 months

    ATTRUBY

    Covered when ALL of the following are met:

    ATTRUBY initial criteria: Patient diagnosed with wild‑type or hereditary transthyretin‑mediated amyloidosis cardiomyopathy (ATTR‑CM); diagnosis confirmed by either (A) cardiac biopsy with positive Congo red stain and ATTR confirmation by mass spectrometry or immunofluorescence, OR (B) ALL of: serum kappa/lambda free light chain ratio 0.26–1.65, absence of monoclonal protein on serum immunofixation, absence of monoclonal protein on urine immunofixation, and myocardial uptake on 99mTc‑PYP with heart‑to‑contralateral ratio >1.5 or visual grade ≥2; patient has clinical history of heart failure (prior hospitalization or symptomatic cardiomyopathy), is negative for light‑chain amyloidosis, and has NYHA class I–III heart failure; prescriber is or in consultation with a cardiologist

    Coverage duration 12 months; may not be used concurrently with ONPATTRO or TEGSEDI

    ATTRUBY renewal criteria: Patient has been seen by prescriber within past 12 months; medication has demonstrated efficacy; patient continues to have NYHA class I–III heart failure

    Coverage duration 12 months

    Erythropoiesis-stimulating agents

    Covered when ANY of the following are met (indications and renewal thresholds summarized):

    ESAs (Aranesp) criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for CKD (adults not on dialysis): hemoglobin <10 g/dL or dose reduction/interruption when Hgb reaches 10 g/dL to decrease transfusion needs; pediatric CKD: hemoglobin approaches or exceeds 12 g/dL guiding dose reduction; cancer chemotherapy contexts align with avoiding RBC transfusion per clinical thresholds; setting may affect Part B vs Part D coverageHgb <10 g/dL (adult CKD)

    Coverage duration 12 months; dosing limited to FDA labeling

    Initial therapy for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

    Covered when ALL of the following diagnostic and clinical criteria are met:

    ATTR-CM initial criteria: (1) Diagnosis of wild‑type or hereditary transthyretin‑mediated amyloidosis cardiomyopathy (ATTR‑CM); AND (2) Diagnostic confirmation by EITHER (A) cardiac biopsy with Congo red stain and ATTR confirmation by mass spectrometry or immunofluorescence OR (B) ALL of: serum kappa/lambda free light chain ratio 0.26–1.65; absence of monoclonal protein on serum immunofixation; absence of monoclonal protein on urine immunofixation; myocardial uptake on 99mTc‑PYP with heart‑to‑contralateral ratio >1.5 or visual grade ≥2; AND (3) Clinical history of heart failure with documentation of either prior hospitalization for HF or symptomatic cardiomyopathy (dyspnea, fatigue, syncope, edema); AND (4) Negative for light‑chain amyloidosis; AND (5) NYHA class I, II, or III heart failure

    Prescriber: cardiologist; coverage duration 12 months

    Renewal criteria for ATTR-CM therapy

    Renewal covered when ALL of the following are met:

    ATTR-CM renewal criteria: (1) Patient seen by prescriber within past 12 months; (2) Medication has demonstrated efficacy; (3) Patient continues to have NYHA class I, II, or III heart failure

    Coverage duration 12 months

    Antipsychotics (selected agents) - new start criteria

    Covered for new‑start patients when ALL of the following are met:

    Antipsychotic new start: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; AND (2) Inadequate response or medical contraindication to two of the following alternatives: lurasidone, risperidone, ziprasidone, olanzapine, quetiapine (IR), quetiapine (XR), or aripiprazole

    Prescriptions limited to FDA labeled dosing; coverage duration 12 months

    Benlysta (subcutaneous) initial criteria

    Covered when ALL of the following are met for active SLE or lupus nephritis:

    Benlysta SLE criteria: For active, autoantibody‑positive SLE without severe active CNS disease: diagnosis supported by anti‑dsDNA >30 IU/mL OR low complement (C3/C4) OR positive anti‑Smith; patient will continue standard‑of‑care therapy (antimalarials, corticosteroids, or immunosuppressants) in combination with Benlysta; inadequate response or contraindication to two of: hydroxychloroquine, immunosuppressive agents (mycophenolate, azathioprine, methotrexate, oral cyclophosphamide), or oral corticosteroids; for active lupus nephritis: continue standard of care and inadequate response or contraindication to mycophenolate mofetil or cyclophosphamide

    Renewal requires positive response and visit within last 14 months; prescriber rheumatologist/nephrologist/dermatologist; coverage 12 months

    Bosentan (oral) initial criteria for Group 1 PAH

    Covered when ALL of the following are met for Group 1 PAH:

    Bosentan PAH criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; AND (2) For Group 1 PAH: right heart catheterization confirming mean PAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; AND (3) Patient does not have ALT/AST >3× ULN or bilirubin increase ≥2× ULNALT/AST <=3×ULN; bilirubin <2×ULN

    Prescriber cardiologist or pulmonologist; coverage 12 months; contraindicated with cyclosporine A or glyburide

    Cayston (aztreonam) initial criteria

    Covered when ALL of the following are met:

    Cayston CF criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; AND (2) Patient with cystic fibrosis documented to have Pseudomonas aeruginosa in the lungs

    Renewal requires visit within last 12 months and positive response; prescriber from CF center, infectious disease, or pulmonology; coverage 12 months

    Cimzia (certolizumab) initial criteria

    Covered when ALL of the following are met for the listed autoimmune diseases:

    Cimzia criteria: Diagnosis of the indicated condition (psoriatic arthritis, RA, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, non‑radiographic axial disease) with medical contraindication or inadequate response to at least two preferred drugs as specified per indication

    May not be used concurrently with other biologic therapies; prescriber rheumatologist/dermatologist/gastroenterologist; coverage 12 months

    Oncology/targeted oral agents - general initial criteria

    Covered when ALL of the following are met:

    Oncology oral agents criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; AND (2) Genetic testing completed if required and results indicate appropriateness; AND (3) No unsupported FDA‑labeled limitation of use for the indication; AND (4) Agent is FDA‑labeled or compendia‑supported as first‑line OR there is inadequate response/contraindication to first‑line therapy OR patient currently/previously benefited from agent

    Renewal requires positive response; typical initial coverage six months; dosing limited to FDA labeling

    Example: Corlanor

    Corlanor (ivabradine): Patient does not have an FDA‑labeled limitation or contraindication to therapy; prerequisite therapy as specified per indication; dose limited to FDA labeling

    Coverage duration 12 months

    Cosentyx

    Cosentyx: Diagnosis of an FDA‑approved indication; may not be used concurrently with other biologic therapies; prescribed by or in consultation with dermatologist or rheumatologist; dose limited to FDA labeling

    Prerequisite therapy required; coverage 12 months

    Cresemba

    Cresemba: Prescribed by disease/transplant/hematology or oncology specialist; initial coverage three months then six months if positive response; dose limited to FDA labeling

    Prerequisite therapy not required

    Deferasirox

    Deferasirox initial criteria: Either (1) chronic iron overload due to non‑transfusion‑dependent thalassemia with LIC ≥5 mg Fe/g dry weight AND serum ferritin >300 mcg/L, OR (2) chronic iron overload due to transfusions with regular transfusions AND serum ferritin >1000 mcg/L; prescriber hematologist/oncologist; renewal requires visit within past 12 months and positive responseLIC >=5 mg Fe/g; ferritin thresholds as stated

    Coverage duration 12 months; dose limited to FDA labeling

    Deferiprone

    Deferiprone: Diagnosis of FDA‑approved indication; for transfusion‑induced iron overload ensure ANC >1.5 x10^9/L; prior inadequate response or contraindication to other chelators (e.g., deferasirox); renewal requires visit within past 12 months and positive response; prescriber hematologist/oncologistANC >1.5 x10^9/L

    Coverage 12 months; dose limited to FDA labeling

    Dihydroergotamine

    Dihydroergotamine for acute migraine: Diagnosis of acute migraine (with/without aura); inadequate response or contraindication to two triptans (e.g., sumatriptan, naratriptan, rizatriptan); may not be used concurrently with another acute migraine agent such as a triptan or acute CGRP antagonist; prescriber neurologist/pain/headache specialistFailure of two triptans

    Renewal requires positive response; coverage 12 months

    Dronabinol

    Dronabinol (CINV): For CINV: inadequate response or contraindication to a 5‑HT3 receptor antagonist AND inadequate response or contraindication to prochlorperazine AND patient is receiving chemotherapy; may be Part B or Part D depending on setting; dose limited to FDA labeling

    Coverage duration pending CMS review; prerequisite therapy required

    Dupixent

    Dupixent: May not be used concurrently with another monoclonal antibody; for atopic dermatitis: moderate‑to‑severe disease with ≥10% BSA or involvement of special areas and inadequate response or contraindication to one topical corticosteroid or topical calcineurin inhibitor; for asthma: eosinophilic or steroid‑dependent moderate‑to‑severe asthma with pretreatment eosinophils ≥150 cells/µL and inadequate control despite inhaled steroid plus another maintenance med; for eosinophilic esophagitis: EGD with biopsy and inadequate response or contraindication to one PPI or swallowed topical steroids; prescriber specialty required; coverage 12 monthsEosinophils >=150 cells/µL for eosinophilic asthma

    Prerequisite therapy required; dose limited to FDA labeling

    Emgality

    Emgality: May not be used concurrently with other CGRP antagonists for migraine prevention; patients age ≥18 for listed indications; initial coverage: migraine prevention 6 months, episodic cluster headache 3 months; renewals 12 months; dose limited to FDA labelingAge >=18

    Prerequisite therapy required

    Enbrel

    Enbrel: Diagnosis‑specific prior inadequate response or contraindication to required therapies (e.g., methotrexate for RA; NSAID for ankylosing spondylitis; topical/systemic therapies for psoriasis) and medical contraindication or inadequate response to at least one preferred adalimumab biosimilar (Hadlima or Simlandi); prescriber specialty required; dose limited to FDA labelingPrior failure of preferred adalimumab biosimilar

    Renewal: treatment goals met; coverage 12 months

    Glutamine (sickle cell)

    Glutamine (sickle cell): Diagnosis of sickle cell disease and ≥2 painful crises in prior 12 months despite hydroxyurea unless hydroxyurea is contraindicated; age ≥5 years; prescriber specialist required>=2 painful crises in prior 12 months

    Coverage duration 12 months; dose limited to FDA labeling

    Epidiolex

    Epidiolex: New starts: diagnosis of seizures associated with Lennox‑Gastaut, Dravet, or tuberous sclerosis complex AND inadequate response or contraindication to two antiseizure medications; prescriber neurologyFailure of two antiseizure medications

    Coverage duration 12 months; dose limited to FDA labeling

    Erleada

    Erleada: Indication per FDA (NMCRPC high risk or MCSPC) with documentation of castrate testosterone <50 ng/dL or bilateral orchiectomy or concurrent GnRH analog; dose limited to FDA labelingTestosterone <50 ng/dL

    Coverage duration six months

    Eucrisa

    Eucrisa: Diagnosis of mild‑to‑moderate atopic dermatitis and inadequate response or contraindication to two of: prescription‑strength topical corticosteroid, pimecrolimus cream, or tacrolimus ointment (pimecrolimus/tacrolimus not required for <2 years)Failure of two topical therapies

    Coverage duration 12 months

    Specialty antimicrobials and related agents

    Default specialty antimicrobial and related agent coverage:

    Specialty antimicrobials default: Diagnosis of an FDA‑approved indication not excluded from Part D; patient must not have an FDA‑labeled limitation of use or contraindication to therapy; dose limited to FDA labeling; renewal requires positive response to therapy

    Coverage duration typically 12 months; setting may affect Part B vs Part D determination

    Default product criteria

    Default coverage applied to many products in this section:

    Default requirements: (1) Diagnosis of an FDA‑approved indication not otherwise excluded from Part D; (2) Patient must not have an FDA‑labeled limitation of use or contraindication to therapy; (3) Dose limited to within FDA‑labeled dosing guidelines; (4) Renewal requires positive response to therapy; (5) Coverage duration typically 12 months

    Applies to many listed products

    FINTEPLA criteria

    Covered when ALL of the following are met for new starts:

    FINTEPLA new start: Diagnosis of an FDA‑approved indication not excluded from Part D; for Lennox‑Gastaut syndrome (LGS): medical contraindication or inadequate response to at least two other seizure medications (e.g., felbamate, lamotrigine, topiramate, clobazam, rufinamide)

    Renewal for Dravet requires positive response; coverage 12 months

    GATTEX criteria

    Covered when ALL of the following are met:

    GATTEX initial: Treatment of short bowel syndrome in patients dependent on parenteral nutrition for ≥1 year with inability to taper parenteral support; adults require recent colonoscopy with polyp removal as applicable; pediatric FOBT/colonoscopy requirements; dose limited to 0.05 mg/kg/day0.05 mg/kg/day

    Initial coverage three months then 12 months if renewal criteria met; prescriber gastroenterologist

    Concurrency/exclusion rules

    Concurrency/exclusion rules (examples):

    Hadlima concurrency: Hadlima may not be used concurrently with other biologic therapies

    Prescriber in consultation with appropriate specialist; coverage 12 months

    Haegarda concurrency: Haegarda may not be used concurrently with another HAE prophylaxis agent

    Prescribed by or in consultation with hematology/allergy/immunology; coverage six months

    INBRIJA criteria

    INBRIJA initial authorization covered when ALL of the following are met:

    INBRIJA initial: (1) Diagnosis of Parkinson's disease with OFF episodes; (2) Provider attestation patient has or will receive inhaler technique education; (3) Patient is taking carbidopa/levodopa; (4) Patient has tried and failed at least one adjunct agent (rasagiline, ropinirole, entacapone, pramipexole, rotigotine, or selegiline) for ≥4 weeks in combination with carbidopa/levodopa; (5) Patient has no underlying lung disease OR if FEV1 <50% provider attests benefits outweigh risks and INBRIJA was not ineffective due to inspiratory capacity

    Age ≥18; prescriber neurologist; renewal requires positive response; dose limited to FDA labeling

    IMBRUVICA criteria

    Covered when ANY of the following diagnosis‑specific conditions are met:

    IMBRUVICA indications: Diagnosis of an FDA‑approved indication (e.g., CLL/SLL, Waldenstrom's, chronic GVHD after failure of ≥1 systemic therapy); for certain tablet strengths document intolerance or contraindication to preferred strengths/forms

    Coverage duration six months; renewal requires positive response; prescriber specialty as indicated

    INBRIJA Initial Therapy

    Initial authorization covered when ALL of the following are met:

    INBRIJA initial criteria: See INBRIJA criteria: Parkinson's disease with OFF episodes, education attestation, carbidopa/levodopa use, prior adjunct agent trial/failure, pulmonary assessment

    Prescriber: neurologist or in consultation with neurologist; age ≥18; renewal requires positive response

    JAYPIRCA Initial Therapy

    JAYPIRCA — Initial authorization covered when ALL of the following are met:

    JAYPIRCA initial criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; AND (2) For CLL/SLL: patient has received ≥2 prior therapies including a BTK inhibitor and a BCL‑2 inhibitor; OR for MCL: patient has received ≥2 prior systemic therapies including a BTK inhibitor

    Coverage duration six months; renewal requires positive response; dose limited to FDA labeling

    Tolvaptan Initial Therapy

    Tolvaptan — Initial authorization covered when ALL of the following are met:

    Tolvaptan initial criteria: (1) Diagnosis of an FDA‑approved indication not excluded from Part D; AND (2) For rapidly‑progressing ADPKD prescriber attests to characteristics such as reduced/declining renal function or high/increasing height‑adjusted total kidney volume

    Exclusions: concurrent use with SAMSCA (tolvaptan tablets) and use in stage 5 CKD; prescriber nephrologist; coverage 12 months

    KALYDECO Initial Therapy

    KALYDECO — Initial authorization covered when ALL of the following are met:

    KALYDECO initial criteria: (1) Diagnosis of cystic fibrosis; AND (2) Patient has at least one CFTR mutation responsive to the prescribed drug based on in vitro assay data; AND (3) Patient is not homozygous for the F508del mutation

    Prescriber CF center specialist or pulmonologist; may not be used concurrently with another CFTR modulator for requested indication; renewal: seen within last 12 months and positive response; coverage 12 months

    KINERET Initial Therapy

    KINERET — Initial authorization covered when ANY of the following diagnoses are met:

    KINERET indications: Diagnosis of CAPS (FCAS, Muckle‑Wells, NOMID), OR rheumatoid arthritis with contraindication or inadequate response to at least two preferred drugs, OR deficiency of interleukin‑1 receptor antagonist (DIRA) with genetic confirmation

    May not be used concurrently with other biologic therapies; prescriber specialist required; coverage 12 months

    Linezolid Initial Therapy

    Linezolid (including IV formulations) — Initial authorization covered when ANY of the following are met:

    Linezolid criteria set: (A) Vancomycin‑resistant Enterococcus faecium infection; OR (B) pneumonia caused by susceptible bacteria with inadequate response/contraindication/resistance to two antibiotic classes (beta‑lactams, macrolides, clindamycin, tetracyclines, co‑trimoxazole) OR inadequate response/contraindication/resistance to vancomycin; OR (C) skin and skin structure infection including diabetic foot infection caused by susceptible bacteria with inadequate response/contraindication/resistance to two listed antibiotic classes or vancomycin

    Prescriber: infectious disease/transplant/hematology/oncology; coverage duration three months; dose limited to FDA labeling

    LIVTENCITY Initial Therapy

    LIVTENCITY — Initial authorization covered when ALL of the following are met:

    LIVTENCITY criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for HSCT or SOT patients with active CMV infection: medical contraindication or inadequate response to ganciclovir, valganciclovir, foscarnet, or cidofovir; prescriber transplant or infectious disease specialist or oncologist

    Exclusions: may not be used concurrently with ganciclovir, valganciclovir, foscarnet or cidofovir; coverage eight weeks; dose limited to FDA labeling

    MAVYRET Initial Therapy

    MAVYRET — Initial authorization covered when ALL of the following are met:

    MAVYRET criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; prescribed by or in consultation with gastroenterology/hepatology, infectious disease, or transplant specialist

    Coverage duration 8–16 weeks per diagnosis or FDA labeling; dose limited to FDA labeling

    LYNPARZA Initial Therapy

    LYNPARZA — Initial authorization covered when ANY of the following FDA‑approved indications are met:

    LYNPARZA multiple indication criteria: Indications include maintenance for BRCA‑mutated ovarian/fallopian tube/primary peritoneal cancer after platinum response; combination with bevacizumab for HRD‑positive first‑line maintenance; adjuvant therapy for high‑risk early BRCA‑mutated HER2‑negative breast cancer after chemo; treatment for metastatic BRCA‑mutated HER2‑negative breast cancer after prior chemo; HRR‑mutated mCRPC after progression on enzalutamide or abiraterone; others per FDA labeling

    Coverage duration six months; dose limited to FDA labeling; renewal requires positive response

    Nucala (mepolizumab) — Initial and Renewal Coverage

    Covered when ALL of the following are met:

    Nucala initial criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for severe asthma: pretreatment eosinophil ≥150 cells/µL within prior 12 months; inadequate control despite medium/high‑dose inhaled steroid plus at least one other maintenance medication; inadequate control defined as ≥1 exacerbation requiring systemic corticosteroids ≥3 days in past 12 months OR ≥1 serious exacerbation requiring hospitalization/ER visit in past 12 months; prescriber specialist requiredEosinophils >=150 cells/µL

    Coverage duration 12 months; renewal requires positive response and visit within specified interval

    Ofev (nintedanib) — IPF and other fibrosing ILD Coverage

    Covered when ALL of the following are met:

    Ofev IPF criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for IPF: exclusion of other ILD causes, HRCT pattern consistent with UIP or supportive histopathology, baseline FVC ≥50%, baseline %DLCO ≥30%; inadequate response or contraindication to pirfenidone where applicable; prescriber rheumatologist or pulmonologist; must not have underlying liver diseaseFVC >=50%; %DLCO >=30%

    Renewal requires visit within last 14 months and positive response; coverage 12 months

    Nexletol (bempedoic acid) — Hyperlipidemia Coverage

    Covered when ALL of the following are met:

    Nexletol criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for HeFH or ASCVD with LDL above thresholds: trial of one high‑intensity statin plus ezetimibe concomitantly for specified weeks with LDL remaining >70 mg/dL OR documented statin intolerance (rhabdomyolysis to one statin or intolerance to both atorvastatin and rosuvastatin); prescriber cardiologist/endocrinologist or lipid specialistLDL > 70 mg/dL

    Coverage duration 12 months; dose limited to FDA labeling

    IGF-1 therapy for growth failure — Initial and Renewal Coverage

    Covered when ALL of the following are met:

    IGF-1 deficiency criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for severe primary IGF‑1 deficiency or GH gene deletion with neutralizing antibodies to GH: height SDS ≤‑3.0 AND basal IGF‑1 SDS ≤‑3.0; prescriber endocrinologistheight SDS <= -3.0; basal IGF-1 SDS <= -3.0

    Renewal requires positive response; coverage 12 months

    Nitazoxanide — Giardiasis/Cryptosporidium

    Covered when ALL of the following are met:

    Nitazoxanide criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for diarrhea due to Giardia lamblia or Cryptosporidium parvum; patient age ≥12 yearsAge >= 12

    Coverage duration 10 days; dose limited to FDA labeling

    Mifepristone (300 mg) — Endogenous Cushing's Disease

    Covered when ALL of the following are met:

    Mifepristone criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; for endogenous Cushing's disease: patient has type 2 diabetes or glucose intolerance by 2‑hour GTT and has failed surgical resection or is not a surgical candidate; prescriber endocrinologist

    Initial coverage six months then 12 months if renewal criteria met; dose limited to FDA labeling

    Nuedexta — Pseudobulbar affect

    Covered when ALL of the following are met:

    Nuedexta criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; structural neurological condition causing pseudobulbar affect; prescriber psychiatrist or neurologist

    Coverage duration 12 months

    Droxidopa — Neurogenic orthostatic hypotension (NOH)

    Covered when ALL of the following are met:

    Droxidopa criteria: Diagnosis of symptomatic neurogenic orthostatic hypotension (NOH) due to primary autonomic failure, dopamine beta‑hydroxylase deficiency, or non‑diabetic autonomic neuropathy; documented orthostatic BP drop ≥20 mmHg systolic or ≥10 mmHg diastolic within 3 minutes of standing; trial and failure or contraindication to at least two first‑line therapies (e.g., fludrocortisone and midodrine); prescriber cardiologist or neurologistBP drop >=20 systolic or >=10 diastolic

    Initial one month then three months if renewal criteria met; dose limited to FDA labeling

    Nurtec ODT — Migraine

    Covered when ALL of the following are met:

    Nurtec criteria: Diagnosis of an FDA‑approved migraine indication not excluded from Part D; patient age ≥18; not used concurrently with other CGRP antagonists for migraine prevention; prior therapy requirements per CMS review/policy where notedAge >=18

    Initial six months then 12 months if positive response; dose limited to FDA labeling

    Initial criteria for oncology/specialty drugs

    General initial coverage for oncology/specialty agents:

    Oncology/specialty agent initial criteria: (1) Diagnosis of an FDA‑approved indication not otherwise excluded from Part D; (2) Genetic testing completed if required and results indicate appropriateness; (3) No unsupported FDA‑labeled limitation of use; (4) Agent is FDA‑labeled or compendia‑supported as first‑line OR inadequate response/contraindication to first‑line therapy OR patient currently/previously benefited from agent

    Typical initial coverage: six months; renewal requires positive response; dosing limited to FDA labeling

    ORKAMBI

    ORKAMBI — Initial authorization covered when ALL of the following are met:

    ORKAMBI initial criteria: Diagnosis of cystic fibrosis AND patient is homozygous for the F508del CFTR mutation; not used concurrently with another CFTR modulator for the requested indication; prescriber CF specialist or pulmonologist

    Renewal: seen within last 12 months and positive response; coverage 12 months; dose limited to FDA labeling

    OPSUMIT (PAH)

    OPSUMIT — Initial authorization covered when ALL of the following are met:

    OPSUMIT initial criteria: Diagnosis of Group 1 pulmonary arterial hypertension confirmed by right heart catheterization with mean PAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; prescriber cardiologist or pulmonologist

    Coverage duration 12 months; dose limited to FDA labeling

    Pirfenidone / IPF

    Pirfenidone — Initial authorization covered when ALL of the following are met:

    Pirfenidone initial criteria: Diagnosis of IPF with exclusion of other ILD causes and HRCT/histopathology consistent with IPF; baseline FVC ≥50% and DLCO ≥30%; patient does not have underlying liver diseaseFVC >=50%; DLCO >=30%

    Coverage duration 12 months; renewal requires follow‑up visit and positive response

    PLEGRIDY

    PLEGRIDY — Initial authorization covered when ALL of the following are met:

    PLEGRIDY initial criteria: Diagnosis of a relapsing form of multiple sclerosis (clinically isolated syndrome, relapsing‑remitting, active secondary progressive) AND medical contraindication or inadequate response to one of: teriflunomide, dimethyl fumarate, fingolimod, or glatiramer acetate

    Coverage duration 12 months; specialist involvement required

    REPATHA (PCSK9 inhibitors)

    REPATHA — Initial coverage when ALL of the following are met:

    REPATHA initial: Diagnosis of an FDA‑approved indication not excluded from Part D; for HeFH or adults with ASCVD on lipid‑lowering therapy with LDL >70 mg/dL: trial of one high‑intensity statin plus ezetimibe concomitantly for specified minimum weeks with LDL remaining >70 mg/dL OR documented statin intolerance (rhabdomyolysis to one statin or intolerance to both atorvastatin and rosuvastatin); prescriber cardiologist/endocrinologist or lipid specialist; not used concurrently with PRALUENT or LEQVIO; dose limited to FDA labelingLDL > 70 mg/dL

    Document duration of statin/ezetimibe trial; coverage duration 12 months

    REPATHA (PCSK9 inhibitor) — Initial coverage criteria

    REPATHA — Initial coverage criteria (expanded):

    REPATHA initial coverage criteria: As above: documented diagnosis; trial of high‑intensity statin + ezetimibe for specified weeks with LDL >70 mg/dL OR documented statin intolerance; prescriber specialty required; not concurrent with PRALUENT or LEQVIO; dosing per FDALDL > 70 mg/dL

    Coverage duration and documentation of trials required

    REZDIFFRA (NASH agent) — Initial and renewal criteria

    REZDIFFRA — Initial and renewal coverage:

    REZDIFFRA initial: Diagnosis of MASH/NASH with moderate–advanced fibrosis; confirmation by liver biopsy (NAS ≥4 with component scores) OR elastography/transient elastography/MRI/CT demonstrating staging consistent with F2 or F3 fibrosis; used in combination with diet and exercise counseling; dose limited to FDA labelingStage F2 or F3 fibrosis

    Renewal requires ≥1 year of therapy, no worsening of fibrosis or progression to F4, and prescriber confirmation of ongoing diet/exercise counseling

    RETACRIT

    RETACRIT — Coverage conditions vary by clinical circumstance:

    RETACRIT coverage: Coverage may be under Medicare Part B or Part D depending on setting and indication; initial/renewal durations vary by indication (e.g., anemia from chemo/CKD without dialysis/zidovudine: initial/renewal 12 months; surgery: 1 month)

    Documentation of use and setting may be required to determine Part B vs Part D coverage

    RUBRACA

    RUBRACA — Initial authorization covered when ALL of the following are met:

    RUBRACA initial: Diagnosis of an FDA‑approved indication not excluded from Part D; examples: MCRPC with deleterious germline/somatic BRCA mutation after AR‑directed therapy and taxane chemotherapy; maintenance for recurrent epithelial ovarian/FT/primary peritoneal cancer with deleterious BRCA mutation after platinum response; no FDA‑labeled contraindication; dose limited to FDA labeling

    Coverage duration six months; renewal requires evidence of positive response

    Biologic agents with specialist prescriber and concurrent therapy restrictions

    Biologic agents with specialist prescriber and concurrent therapy restrictions — covered when ALL of the following are met:

    General biologic criteria: Diagnosis of an FDA‑approved indication; prescribed by or in consultation with specified specialists depending on agent; not used concurrently with other biologic therapies where specified; dose limited to FDA‑labeled dosing; coverage duration commonly 12 months

    Applies to multiple biologic agents listed in this section

    Sodium oxybate (narcolepsy)

    Covered when ALL of the following are met:

    Sodium oxybate criteria: Diagnosis of an FDA‑approved indication (e.g., narcolepsy); patient age ≥7 years; prescribed by provider experienced in management of narcolepsy (neurologist/sleep specialist); not used concurrently with sedative hypnotics; dose limited to FDA labeling

    Coverage duration 12 months

    General initial coverage criteria

    General initial coverage language applied per product:

    General initial criteria: Diagnosis of an FDA‑approved indication not otherwise excluded from Part D; patient must not have an FDA‑labeled limitation of use or contraindication to therapy; product‑specific diagnostic confirmations or prior therapy requirements apply per product entry

    Coverage duration and other specifics vary by product

    TRIKAFTA

    TRIKAFTA — Initial authorization covered when ALL of the following are met:

    Trikafta initial criteria: Diagnosis of cystic fibrosis; patient has at least one F508del CFTR mutation (homozygous or heterozygous) OR a CFTR mutation responsive in vitro; not used concurrently with other CFTR modulators (concurrent CFTR modulators discontinued prior to initiation)

    Patients age ≥2 years; prescriber pulmonologist or CF center specialist; coverage 12 months

    Tadalafil (PAH)

    Tadalafil (PAH) — Initial authorization covered when ALL of the following are met:

    Tadalafil 20 mg PAH initial criteria: Diagnosis of WHO Group 1 PAH confirmed by right heart catheterization with mean PAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR ≥3 Wood units; negative acute vasodilator test or trial/failure/contraindication to calcium channel blocker therapy; prescriber pulmonologist or cardiologist

    Coverage duration 12 months; dose limited to FDA labeling

    Fentanyl buccal lozenge on a handle

    Fentanyl buccal lozenge on a handle — Initial authorization covered when ALL of the following are met:

    Fentanyl buccal lozenge initial criteria: Diagnosis of breakthrough chronic cancer pain in active cancer; patient has difficulty swallowing or mucositis or related indications; patient is opioid tolerant and has been treated with a long‑acting opioid within past 90 days and has at least one week history of around‑the‑clock opioid therapy demonstrating tolerance (examples: ≥60 mg oral morphine/day; ≥25 mcg/hr transdermal fentanyl; ≥30 mg oral oxycodone/day; ≥60 mg oral hydrocodone/day or equianalgesic dose)Opioid tolerance thresholds as defined

    Coverage duration 12 months

    Trientine

    Trientine — Initial authorization covered when ALL of the following are met:

    Trientine initial criteria: Diagnosis of Wilson's disease confirmed by at least two diagnostic criteria (e.g., ATP7B mutation, Kayser‑Fleischer rings, neurological symptoms, hepatic abnormality, low ceruloplasmin <20 mg/dL, urinary copper >40 mcg/24h, hepatic parenchymal copper >40 mcg/g dry weight); intolerance or contraindication to penicillamine; prescriber specialist in genetics/metabolism or hepatology

    Initial six months then 12 months if renewal criteria met; dose limited to FDA labeling

    Venclexta

    Venclexta — Covered when ANY of the following qualifying indications are met:

    Venclexta initial eligible indications: (1) Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); OR (2) In combination with azacitidine, decitabine, or low‑dose cytarabine for newly diagnosed AML in adults ≥75 years or with comorbidities precluding intensive induction chemotherapy

    Initial approval six months; renewal requires positive response

    Talzenna

    Talzenna — Initial authorization covered when ANY of the following are met:

    Talzenna initial indications: Single‑agent for deleterious or suspected deleterious germline BRCA‑mutated HER2‑negative locally‑advanced or metastatic breast cancer; OR in combination with enzalutamide for HRR gene‑mutated mCRPC; diagnosis must be FDA‑approved indication not excluded from Part D

    Coverage duration six months; dose limited to FDA labeling

    Somavert

    Somavert — Initial authorization covered when ALL of the following are met:

    Somavert initial criteria: Diagnosis of acromegaly with confirmation by GH level criteria after OGTT or appropriate clinical/histopathologic confirmation; inadequate response or contraindication to octreotide; prescriber specialty as indicated

    Initial six months then 12 months if renewal met; dose limited to FDA labeling

    Valchlor

    Valchlor — Covered when ALL of the following are met:

    Valchlor initial criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; patient has received at least one prior skin‑directed therapy (e.g., topical corticosteroids, bexarotene gel)

    Approvals limited to two 60 g tubes per month; initial six months then 12 months if renewal criteria met

    VALCHLOR — Initial and Renewal Criteria

    VALCHLOR — Initial and renewal criteria:

    VALCHLOR initial criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; patient has received at least one prior skin‑directed therapy (topical corticosteroids, bexarotene topical gel)

    Quantity limited to two 60‑gram tubes per month; initial 6 months then 12 months if renewal criteria met

    VENCLEXTA — Initial and Renewal Criteria

    VENCLEXTA — Initial and renewal coverage:

    VENCLEXTA initial criteria: Diagnosis of an FDA‑approved indication not otherwise excluded from Part D AND (a) for CLL/SLL treatment of adults OR (b) in combination with azacitidine, decitabine, or low‑dose cytarabine for newly diagnosed AML in adults ≥75 or with comorbidities precluding intensive induction chemotherapy

    Dose limited to FDA‑labeled dosing; initial coverage six months; renewal requires positive response

    VERQUVO — Initial and Renewal Criteria

    VERQUVO — Covered when ALL of the following are met:

    VERQUVO initial criteria: Diagnosis of an FDA‑approved indication not excluded from Part D; ejection fraction <45%; AND one of: ≥1 prior HF hospitalization in last 6 months OR outpatient IV diuretic within last 3 months; AND inadequate response or contraindication to at least two guideline therapy classes (ACEi/ARB/ARNI, beta‑blockers, aldosterone antagonists, or SGLT2 inhibitor)EF <45%

    Prescriber cardiologist or consult; coverage 12 months; renewal requires positive response

    VOWST — Initial Criteria

    VOWST — Initial authorization covered when ALL of the following are met:

    VOWST initial criteria: Diagnosis of recurrent Clostridioides difficile infection defined as three or more prior CDI episodes treated with antibiotics (e.g., vancomycin); patient completed antibiotic therapy 2–4 days prior to initiating VOWST; patient completed magnesium citrate bowel prep the day before and at least 8 hours prior to initiating VOWST

    Limited to a single treatment course; duration 10 days; dose limited to FDA labeling

    WINREVAIR (PAH) — Initial Criteria

    WINREVAIR (PAH) — Initial authorization covered when ALL of the following are met:

    WINREVAIR initial criteria: Diagnosis of Group 1 PAH confirmed by right heart catheterization with mean PAP ≥20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units; inadequate response or contraindication to two of the following oral therapies: PDE5 inhibitors, endothelin receptor antagonists, or other specified agents; prescriber pulmonologist or cardiologist

    Coverage 12 months; dosing limited to FDA labeling

    XALKORI — Initial and Renewal Criteria

    XALKORI — Initial and renewal coverage (ANY of the listed qualifying diagnoses):

    XALKORI qualifying criteria: ROS1‑positive metastatic NSCLC; anaplastic large cell lymphoma (ALCL); inflammatory myofibroblastic tumor (IMT); metastatic NSCLC ALK‑positive with intolerance/contraindication to alectinib; or patient currently receiving or previously benefited from XALKORI for cancer treatment

    Genetic testing completed if applicable; coverage 6 months; renewal requires positive response

    XELJANZ — Initial Criteria by Indication (step therapy required)

    XELJANZ — Covered when ALL of the following are met per indication (step therapy required):

    XELJANZ for Psoriatic Arthritis: Diagnosis of psoriatic arthritis AND medical contraindication or inadequate response to at least two preferred drugs as listed

    May not be used concurrently with other biologic therapies; prescriber or consult required; coverage 12 months

    XELJANZ for Rheumatoid Arthritis: Diagnosis of rheumatoid arthritis AND medical contraindication or inadequate response to at least two preferred drugs as listed

    Prescribed by or in consultation with rheumatologist; coverage 12 months

    XELJANZ for Ulcerative Colitis: Diagnosis of ulcerative colitis AND medical contraindication or inadequate response to at least two preferred drugs as listed

    Prescribed by or in consultation with gastroenterologist; coverage 12 months

    XERMELO — Initial and Renewal Criteria

    XERMELO — Covered when ALL of the following are met:

    XERMELO initial: Diagnosis of an FDA‑approved indication not excluded from Part D; diarrhea inadequately controlled with a somatostatin analog (SSA) such as octreotide for at least 3 months; used in combination with SSA therapy

    Renewal requires positive response (reduction in daily stools); initial six months then 12 months if renewed

    XIFAXAN — Indication-specific Criteria and Limits

    XIFAXAN — Indication‑specific criteria and limits:

    XIFAXAN indications: Hepatic encephalopathy when lactulose dose limited by side effects; travelers' diarrhea due to noninvasive E. coli with trial/failure or documented resistance to specified antibiotics; moderate‑to‑severe IBS‑D without constipation with inadequate response to first‑line therapy; dosing and duration per indication (e.g., 550 mg TID x14 days for IBS‑D; retreatment limited)

    Coverage durations: hepatic encephalopathy 12 months, IBS‑D 14 days (retreatment limits), travelers' diarrhea 3 days

    XOLAIR — Initial Criteria by Indication

    XOLAIR — Initial criteria by indication (examples):

    XOLAIR severe asthma criteria: Severe asthma with positive skin prick or blood test to a perennial aeroallergen and baseline IgE ≥30 IU/mL; inadequate asthma control despite medium/high‑dose inhaled corticosteroid plus at least one other maintenance med; inadequate control defined as ≥1 exacerbation requiring oral systemic corticosteroids for ≥3 days in past 12 months OR ≥1 serious exacerbation requiring hospitalization/ER visit in past 12 monthsIgE >=30 IU/mL

    May not be used concurrently with another monoclonal antibody; prescriber specialist required; coverage 12 months

    XOLAIR Coverage Criteria

    XOLAIR — Initial and renewal coverage elements:

    XOLAIR initial severe asthma: Positive allergen testing and baseline IgE ≥30 IU/mL; inadequate control despite inhaled corticosteroid + another maintenance med; inadequate control defined by exacerbation/hospitalization criteria

    Renewal requires evidence of positive response (decreased exacerbations, decreased rescue med use, symptom reduction, or improved FEV1); coverage 12 months

    XOLAIR other indications: Chronic urticaria: inadequate response to maximally tolerated H1 antihistamine; chronic rhinosinusitis with nasal polyps: ongoing intranasal corticosteroid use or failure/contraindication to intranasal corticosteroids

    May not be used concurrently with another monoclonal antibody

    XTANDI Coverage Criteria

    XTANDI — Initial and renewal coverage criteria:

    XTANDI initial criteria: Diagnosis of NMCRPC with high‑risk features or other indicated prostate cancer state; patient has bilateral orchiectomy OR castrate testosterone <50 ng/dL OR concurrent GnRH analog therapyCastration‑level testosterone <50 ng/dL

    Coverage duration six months; dose limited to FDA labeling; renewal requires continued castrate status

    ZEJULA Coverage Criteria

    ZEJULA — Initial and renewal coverage criteria:

    ZEJULA initial maintenance: First‑line maintenance for adult patients with advanced epithelial ovarian/fallopian tube/primary peritoneal cancer in complete or partial response to first‑line platinum chemotherapy; OR maintenance for recurrent deleterious/suspected deleterious gBRCA‑mutated disease in response to platinum chemotherapy

    Coverage duration six months; renewal requires positive response; dosing limited to FDA labeling

    YESINTEK Coverage Criteria

    YESINTEK — Covered when ALL of the following are met:

    YESINTEK general: Diagnosis of an FDA‑approved indication not excluded from Part D; prescriber is or in consultation with rheumatologist/dermatologist/gastroenterologist as appropriate; may not be used concurrently with other biologic therapies; dose limited to FDA labeling

    Coverage duration 12 months; required medical information pending CMS review

    ZURZUVAE Coverage Criteria

    ZURZUVAE — Covered when ALL of the following are met:

    ZURZUVAE initial: Diagnosis per FDA‑approved indication not excluded from Part D; required medical information and prerequisites as noted in the policy; dose limited to FDA labeling

    Coverage duration 14 days; further documentation pending CMS review

    Many biologic and monoclonal antibody products in this policy are subject to concurrent‑use prohibitions. Examples across product entries include: Actemra, Cimzia, Cosentyx, Benlysta, Enbrel, Hadlima, Haegarda, Kineret, and other listed biologics which may not be used concurrently with other biologic or monoclonal antibody therapies. In addition, several products specify that concurrent use with other agents in the same mechanistic class is disallowed (for example, REPATHA concurrent use with PRALUENT or LEQVIO is prohibited). These concurrency restrictions are enforced as exclusion criteria and may trigger denial if concurrent therapy is documented.

    Adempas (riociguat) has an explicit drug‑interaction exclusion: it must not be used concurrently with nitrates, nitric oxide donors, phosphodiesterase (PDE) inhibitors, or non–specific PDE inhibitors. This interaction is listed as an exclusion and may trigger denial if concurrent use is present; prescribers must document absence of these concomitant agents in the medical record.

    Adbry (tralokinumab) is contraindicated for concurrent use with another monoclonal antibody therapy per the policy. Requests documenting simultaneous monoclonal antibody treatment may be denied unless the provider demonstrates a compelling, documented rationale and that such use is consistent with FDA labeling or other policy exceptions.

    For the transthyretin amyloid therapy listed (ATTRUBY), the policy specifies an exclusion for combined therapy with RNA‑targeting agents: ATTRUBY may not be used concurrently with Onpattro (patisiran) or Tegsedi (inotersen). Concurrent use is an explicit exclusion and may result in denial.

    Where CFTR modulators are addressed (including Trikafta and other CFTR agents), the policy requires that concurrent CFTR modulator therapy is not permitted. Specifically, CFTR modulators must be discontinued prior to initiation of another CFTR modulator product; concurrent use is listed as an exclusion and may lead to denial.

    The policy repeatedly states that certain biologic treatments are not to be combined with other biologics. Examples include Benlysta, Cimzia, Cosentyx, and similar agents — each entry notes that the product may not be used concurrently with other biologic therapies. Providers should document discontinuation of other biologics prior to initiation or risk denial.

    Bosentan (oral) carries product‑specific concurrency exclusions: it is contraindicated with cyclosporine A and glyburide. In addition, monitoring and lab thresholds (liver enzymes and bilirubin) are required per the bosentan entry; concurrent contraindicated medications or unacceptable lab values are exclusionary.

    Cosentyx (secukinumab) is listed with a clear concurrency prohibition: it may not be used concurrently with other biologic therapies. The entry directs specialist prescribing and limits dosing to FDA‑labeled regimens; concurrent biologic use is an exclusion that may trigger denial.

    Dupixent (dupilumab) is explicitly restricted from concurrent use with other monoclonal antibody therapies. Indication‑specific prerequisites and specialist involvement are required, and documentation of absence of concurrent monoclonal therapy should accompany requests.

    Emgality (galcanezumab) for migraine prevention is subject to a class concurrency exclusion: the policy states Emgality may not be used concurrently with other CGRP antagonists for migraine prevention. Age and prerequisite therapy requirements also apply for initial approvals.

    Enbrel (etanercept) is identified as a biologic that may not be used concurrently with other biologic therapies. The Enbrel criteria also require prior inadequate response or contraindication to a preferred adalimumab biosimilar (e.g., Hadlima or Simlandi) before approval in many indications.

    Dihydroergotamine for acute migraine is listed with a concurrency exclusion against other acute migraine agents: it may not be used concurrently with triptans or acute CGRP antagonists. Prior triptan trials and specialist prescribing are required elements of initial authorization.

    The policy contains a broad exclusion that any product will not be approved when the patient has an FDA‑labeled limitation of use or contraindication. This is applied across many entries — requests documenting an FDA‑labeled contraindication or limitation to the requested therapy are excluded and may be denied.

    Initial Authorization / Start-of-Therapy Criteria

    Renewal / Ongoing Therapy Criteria

    Required Prior / Alternative Therapy (Step) Rules

    Step therapy requirementRequired prior trial(s) / documentationNotes
    Antidepressant agents (new starts)
    Inadequate response or medical contraindication to two preferred alternative antidepressants (examples: citalopram, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine, duloxetine)
    Required for new-start patients; coverage duration typically 12 months
    Step therapy requirementRequired prior trial(s) / documentationNotes
    Actemra (selected indications)
    Inadequate response or medical contraindication to at least two preferred drugs (examples: Hadlima, Simlandi, Rinvoq) depending on indication; prescriber is or in consultation with rheumatologist or pulmonologist
    May not be used concurrently with other biologic therapies; coverage duration 12 months
    Step therapy requirementRequired prior trial(s) / documentationNotes
    General step therapy for listed agents (examples: antipsychotics, Cimzia)
    Inadequate response or medical contraindication to two specified preferred alternative therapies (lists provided per indication)
    Applies to new-start patients; prescriber specialty and 12-month coverage common
    Step therapy requirementRequired prior trial(s) / documentationNotes
    Enbrel (etanercept)
    Prior inadequate response or contraindication to at least one preferred adalimumab biosimilar (preferred agents include Hadlima or Simlandi)
    May not be used concurrently with other biologic therapies; prescriber specialty required; coverage duration 12 months
    Step therapy requirementRequired prior trial(s) / documentationNotes
    Dronabinol (for CINV)
    Inadequate response or contraindication to a 5-HT3 receptor antagonist (e.g., ondansetron) AND inadequate response or contraindication to prochlorperazine; patient is receiving chemotherapy
    May be covered under Part B or Part D depending on setting; coverage pending CMS review
    Step therapy requirementRequired prior trial(s) / documentationNotes
    FINTEPLA and similar agents
    Prior inadequate response or medical contraindication to specified alternatives (e.g., for LGS: failure of ≥2 other antiseizure medications)
    Prerequisite therapy required; prescriber specialty often required; coverage duration commonly 12 months
    Step therapy requirementRequired prior trial(s) / documentationNotes
    INBRIJA (inhaled levodopa)
    Trial and failure of at least one adjunct agent for ≥4 weeks in combination with carbidopa/levodopa (examples: rasagiline, ropinirole, entacapone, pramipexole, rotigotine, selegiline); provider attestation of inhaler education and pulmonary assessment
    Patient must be taking carbidopa/levodopa; age ≥18; prescriber neurologist or consult; renewal requires positive response
    Step therapy requirementRequired prior trial(s) / documentationNotes
    JAYPIRCA (zanubrutinib)
    For CLL/SLL: prior exposure to at least two prior therapies including a BTK inhibitor and a BCL-2 inhibitor; for MCL: ≥2 prior systemic therapies including a BTK inhibitor
    Documentation required; coverage duration six months; dose limited to FDA-labeled dosing; prerequisite therapy requirement noted pending CMS review
    Step therapy requirementRequired prior trial(s) / documentationNotes
    KISQALI (ribociclib) regimens
    Medical contraindication or inadequate response to at least one preferred drug (examples: Verzenio or Ibrance) prior to approval
    Prescriber specialty and documentation required; typical initial coverage six months; renewal with positive response
    Step therapy requirementRequired prior trial(s) / documentationNotes
    Nexletol (bempedoic acid)
    Trial of one high-intensity statin plus ezetimibe concomitantly for specified minimum weeks with LDL remaining >70 mg/dL OR documented statin intolerance (rhabdomyolysis to one statin or intolerance to both atorvastatin and rosuvastatin)
    Prescribed by or in consultation with cardiology/endocrinology; documentation of statin/ezetimibe trial duration required; coverage 12 months
    Step therapy requirementRequired prior trial(s) / documentationNotes
    Trial and failure documentation (general)
    Documentation that prior therapies were tried and failed or were contraindicated (examples: trials of first-line agents with clinical response noted)
    Required prior therapy documentation is necessary for initial authorization decisions
    Step therapy requirementRequired prior trial(s) / documentationNotes
    Documentation of prior therapy or contraindication
    Provide documentation of prior therapy trials and outcomes or documented medical contraindications to those therapies (examples vary by product)
    Documentation often required to demonstrate failure of preferred alternatives prior to approval
    Step therapy requirementRequired prior trial(s) / documentationNotes
    REPATHA (PCSK9 inhibitor)
    Trial of one high-intensity statin plus ezetimibe concomitantly for specified minimum weeks with LDL remaining >70 mg/dL OR documented statin intolerance as defined; prescriber specialty documentation required
    May not be used concurrently with Praluent or Leqvio; document duration of statin/ezetimibe trial; dose limited to FDA labeling
    Step therapy requirementRequired prior trial(s) / documentationNotes
    TYENNE (example biologic) prior therapy requirement
    Inadequate response or medical contraindication to preferred drugs (usually at least two preferred agents such as Hadlima, Simlandi, Rinvoq depending on indication)
    Prescribed by or in consultation with rheumatologist; coverage duration 12 months; not to be used concurrently with other biologics
    Step therapy requirementRequired prior trial(s) / documentationNotes
    Valchlor (topical mechlorethamine)
    Patient must have received at least one prior skin-directed therapy (examples: topical corticosteroids or bexarotene topical gel)
    Approvals limited to two 60 g tubes per month; initial 6 months then 12 months if renewal criteria met
    Step therapy requirementRequired prior trial(s) / documentationNotes
    XELJANZ (tofacitinib) step therapy
    Prior inadequate response or medical contraindication to at least two preferred drugs (lists provided by indication) before approval
    May not be used concurrently with other biologic therapies; prescriber specialty required; coverage duration 12 months
    Step therapy requirementRequired prior trial(s) / documentationNotes
    Prerequisite therapy for several products (examples aggregated)
    Many products require prior or concomitant use of standard therapies before approval (examples: Xolair requires inadequate control despite inhaled steroid plus at least one other maintenance med; other agents require prior specific drug trials)
    Prescriber specialty and diagnostic documentation often required; coverage and step details product-specific

    Index and Code Listings

    Product listingsmixed
    VENCLEXTA ORAL TABLET 10 MGVENCLEXTA product listing
    VENCLEXTA STARTING PACKVENCLEXTA starting pack
    100 MGVENCLEXTA strength
    50 MGVENCLEXTA strength
    Products listed in this sectionmixed
    VALCHLORProduct affected
    VERQUVOProduct affected
    VERZENIOProduct affected
    VOSEVIProduct affected
    VOWSTProduct affected
    VUMERITYProduct affected
    WINREVAIRProduct affected
    XALKORIProduct affected
    XATMEPProduct affected
    XDEMVYProduct affected
    1–10 of 15
    1/2
    Product list (no billing codes provided in this section)mixed
    No codes listed
    Indexed product listingsNDC | mixed
    INTRALIPID 20%Intralipid intravenous emulsion 20% (indexed entries)
    INTRALIPID 30%Intralipid intravenous emulsion 30% (indexed entries)
    Indexed drug: ipratropium bromide 0.02%NDC
    ipratropium bromide inhalation solution 0.02%Index entries listing ipratropium bromide inhalation solution 0.02% across many index numbers
    Indexed drug: ipratropium-albuterolNDC
    ipratropium-albuterol inhalation solutionIndex entries listing ipratropium-albuterol inhalation solution across many index numbers
    Indexed ml entriesmixed
    mlmultiple numeric index entries referencing milliliters (ml) across index
    Indexed drug namesNDC
    ITOVEBI ORAL TABLET 3 MG, 9 MGIndex entry for Itovebi oral tablet strengths 3 mg and 9 mg

    Actions, Documentation & Denial Risks for Providers

    Prior Authorization

    Abiraterone prior authorization & dose substitution

    Abiraterone (oral) prior authorization: PA required. Initial requests must document diagnosis of metastatic high‑risk castration‑sensitive prostate cancer (MCSPC) or metastatic castration‑resistant prostate cancer (mCRPC). If the request is for the 500 mg tablet, the provider must document why the 250 mg tablet cannot be used (dose‑substitution rationale). Limit approvals limited to FDA‑labeled dosing. Coverage duration: 6 months. Note: patient must not have any FDA‑labeled contraindication or limitation of use.

    • Coverage duration: 6 months
    • If 500 mg tablet requested, provide rationale why 250 mg tablet unsuitable
    • Limited to FDA‑labeled dosing
    Prior Authorization

    Actemra prior authorization and preferred‑alternative requirements

    Actemra (tocilizumab) — prior authorization required. Initial criteria: document applicable FDA‑approved diagnosis (e.g., rheumatoid arthritis, polyarticular JIA, giant cell arteritis, systemic juvenile idiopathic arthritis, systemic sclerosis–associated ILD) and medical contraindication or inadequate response to required preferred agents (examples include Hadlima, Simlandi, Rinvoq as applicable). Do not use Actemra concurrently with other biologic therapies. Prescriber should be or consult with a rheumatologist or pulmonologist when indicated. Coverage duration: 12 months. Limited to FDA‑labeled dosing.

    • Do not combine with other biologic therapies
    • Prescribed by or in consultation with rheumatologist/pulmonologist as appropriate
    • Preferred‑alternative step requirement: trial of specified preferred agents prior to approval
    • Coverage duration: 12 months
    Documentation Required

    ATTRUBY prior authorization and diagnostic documentation (ATTR‑CM)

    ATTRUBY prior authorization and documentation: PA requires diagnosis of wild‑type or hereditary transthyretin‑mediated amyloid cardiomyopathy (ATTR‑CM) and diagnostic confirmation by either (a) cardiac biopsy with positive Congo red and ATTR confirmation by mass spectrometry or immunofluorescence, or (b) noninvasive workup including serum free light chain ratio and absence of monoclonal protein on serum and urine immunofixation plus myocardial uptake on 99mTc‑PYP (heart‑to‑contralateral ratio >1.5 or visual grade ≥2). Patient must be negative for light‑chain amyloidosis and have NYHA class I–III heart failure with supporting clinical history (e.g., prior HF hospitalization or compatible symptoms). Concurrent use with Onpattro or Tegsedi is prohibited. Renewal requires recent prescriber visit and documented medication efficacy. Coverage duration: 12 months. Prescriber: cardiologist or in consultation with cardiology.

    • Diagnostic confirmation: cardiac biopsy OR nuclear imaging + lab exclusion of light‑chain disease
    • NYHA class I–III required
    • Do not use concurrently with Onpattro or Tegsedi
    • Coverage duration: 12 months
    • Prescribed by or in consultation with a cardiologist
    Prior Authorization

    Adbry prior authorization & concurrent biologic exclusion

    Adbry prior authorization and concurrency exclusion: PA requires documented diagnosis for an FDA‑approved indication (e.g., atopic dermatitis) with specified disease severity (moderate–severe AD with ≥10% BSA or involvement of sensitive sites and intractable pruritus/cracking/bleeding) and prior inadequate response or contraindication to topical therapies (prescription‑strength topical corticosteroid or topical calcineurin inhibitor). Do not use Adbry concurrently with another monoclonal antibody therapy (concurrent biologic exclusion). Prescriber should be an allergist, immunologist, or dermatologist. Coverage duration: 12 months.

    • May not use concurrent monoclonal antibody therapy
    • Prescribed by or in consultation with an allergist/immunologist/dermatologist
    • Coverage duration: 12 months
    • Limited to FDA‑labeled dosing
    Prior Authorization

    Prior authorization requirement and coverage duration (general)

    Prior authorization general requirement and duration notes: Many specialty products require PA with initial documentation of diagnosis, prerequisite/step therapies or genetic testing when applicable, and are limited to FDA‑labeled dosing. Typical coverage durations: 3, 6, or 12 months depending on product (examples above: Abiraterone 6 months; Actemra, ATTRUBY, many biologics 12 months; some products have product‑specific shorter initial durations). Ensure required supporting documentation is submitted with initial requests to avoid denials.

    • Most approvals limited to FDA‑labeled dosing
    • Typical durations: 3, 6, or 12 months (product dependent)
    • Genetic testing or prior therapy documentation may be required for oncology/targeted agents
    Step Therapy

    Antipsychotic agents — prior authorization & step therapy

    Antipsychotic agent prior authorization and step requirements: New starts require diagnosis of an FDA‑approved indication and documentation of inadequate response or contraindication to two alternatives (examples: lurasidone, risperidone, ziprasidone, olanzapine, quetiapine, aripiprazole). Coverage duration typically 12 months. Ensure prescriber and clinical justification are included.

    • Requires trial/failure of two alternatives prior to approval
    • Coverage duration: 12 months
    Prior Authorization

    Cimzia prior authorization & concurrent biologic exclusion

    Cimzia prior authorization and concurrent biologic exclusion: PA requires diagnosis consistent with FDA indications (e.g., psoriatic arthritis, RA, Crohn's disease, plaque psoriasis) and prior inadequate response or contraindication to at least two preferred drugs. Cimzia may not be used concurrently with other biologic therapies. Prescriber should be or consult with relevant specialist (rheumatology, dermatology, gastroenterology). Coverage duration: 12 months.

    • May not use concurrently with other biologic therapies
    • Trial/failure of at least two preferred drugs required
    • Prescribed by or in consultation with specialty (rheumatology/dermatology/gastroenterology)
    • Coverage duration: 12 months
    Prior Authorization

    FINTEPLA prior authorization & prior therapy requirement

    FINTEPLA prior authorization: For Lennox‑Gastaut syndrome (LGS), new starts require documented diagnosis and prior inadequate response or contraindication to at least two other seizure medications (examples: felbamate, lamotrigine, topiramate, clobazam, rufinamide). Prescriber should be or consult with a neurologist. Coverage duration: 12 months. Renewal requires evidence of clinical benefit.

    • Neurologist involvement recommended
    • Requires prior inadequate response to ≥2 antiseizure medications for LGS
    • Coverage duration: 12 months
    Documentation Required

    GATTEX prior authorization & required documentation

    GATTEX prior authorization and documentation: PA requires diagnosis of short bowel syndrome, dependency on parenteral nutrition for ≥1 year, inability to taper parenteral support, and appropriate pretherapy colonoscopy/fecal occult blood testing per age. Prescriber should be or consult with a gastroenterologist. Initial coverage: 3 months then 12 months if renewal criteria met. Dose limited to FDA‑approved dosing (0.05 mg/kg/day).

    • Prescribed by or in consultation with a gastroenterologist
    • Initial coverage 3 months, then 12 months if renewal criteria met
    • Dose limited to FDA‑approved 0.05 mg/kg/day
    Prior Authorization

    Kalydeco prior authorization & CFTR modulator concurrency exclusion

    Kalydeco (ivacaftor) prior authorization and exclusion: PA requires diagnosis of cystic fibrosis with at least one CFTR mutation responsive to the drug per in vitro data and that the patient is not homozygous for F508del for applicable products. Do not use concurrently with another CFTR modulator for the same indication. Prescriber should be or consult with a CF specialist or pulmonologist. Coverage duration: 12 months.

    • May not use concurrently with another CFTR modulator for the requested indication
    • Prescribed by or in consultation with CF treatment center specialist or pulmonologist
    • Coverage duration: 12 months
    Prior Authorization

    Nucala prior authorization — eosinophil & specialist requirements

    Nucala (mepolizumab) prior authorization, specialist prescriber and eosinophil requirement: PA requires documented FDA‑approved diagnosis (e.g., severe eosinophilic asthma) and pre‑treatment blood eosinophil count ≥150 cells/µL within prior 12 months for asthma. Patient must have inadequate control despite medium/high‑dose inhaled corticosteroid plus at least one other maintenance therapy, and documentation of exacerbation history (systemic steroid courses or hospital/ER visits). Nucala may not be used concurrently with another monoclonal antibody therapy. Prescriber should be or consult with an asthma specialist. Coverage duration: 12 months.

    • Pre‑treatment eosinophils ≥150 cells/µL within 12 months for asthma
    • Do not use concurrently with another monoclonal antibody therapy
    • Prescribed by or in consultation with asthma specialist/allergist/pulmonologist
    • Coverage duration: 12 months
    Prior Authorization

    VENCLEXTA prior authorization & required diagnostics

    VENCLEXTA (venetoclax) prior authorization: PA required with documentation of FDA‑approved diagnosis (e.g., CLL/SLL, AML per label) and intended regimen (monotherapy or combination per indication). Genetic testing or disease‑specific diagnostics should be provided if required by the indication. Coverage duration typically 6 months; approvals limited to FDA‑labeled dosing. Ensure no FDA‑labeled contraindications.

    • Coverage duration: 6 months
    • Provide indication‑specific diagnostics/genetic testing when required
    • Limited to FDA‑labeled dosing
    Prior Authorization

    VALCHLOR prior authorization, prior therapy & quantity limit

    VALCHLOR prior authorization and quantity limit: PA requires diagnosis for an FDA‑approved indication and documentation of prior skin‑directed therapy (e.g., topical corticosteroids, bexarotene topical gel). Initial approval: 6 months then 12 months if renewal criteria met. Approvals limited to quantity of two 60 g tubes per month. Ensure no FDA‑labeled contraindication.

    • Initial: 6 months, then 12 months if renewal criteria met
    • Quantity limit: two 60 g tubes per month
    • Prior trial of at least one skin‑directed therapy required
    Prior Authorization

    XALKORI prior authorization & genetic testing requirement

    XALKORI (crizotinib) prior authorization: PA requires documentation of appropriate diagnosis (e.g., ROS1‑positive or ALK‑positive metastatic NSCLC as labeled) and that any required genetic testing has been completed with supportive results. Provide documentation of prior therapy/intolerance only where specified by indication. Coverage duration typically 6 months. Limited to FDA‑labeled dosing.

    • Genetic testing confirming actionable mutation required when applicable
    • Coverage duration: 6 months
    • Limited to FDA‑labeled dosing
    Denial Risk

    Concurrent biologic/monoclonal antibody and other therapy exclusions

    Concurrent biologic / monoclonal antibody exclusions and incompatible concurrent therapies: Many biologic agents (e.g., Actemra, Cimzia, Tyenne, Enbrel, Xeljanz/others where specified) may not be used concurrently with other biologic therapies; specific agents list concurrent‑use prohibitions (also applies to concurrent monoclonal antibodies, CFTR modulators, select RNA therapies). Check the product‑specific exclusion before approving concurrent coverage. Concurrent use of Inbrija with apomorphine is prohibited; Inbrija also requires provider attestation of inhaler education and pulmonary status (FEV1 and lung disease exclusion).

    • Many products: 'May not use concurrently with other biologic therapies' — verify per drug
    • Inbrija: may not use with apomorphine; requires inhaler education attestation and pulmonary function assessment
    • CFTR modulators: do not use multiple modulators concurrently (e.g., Kalydeco, Orkambi, Trikafta)
    Denial Risk

    Age restrictions, FDA‑labeled contraindications & denial risks

    Age‑based and FDA‑labeled contraindication denial risks: Requests must confirm patient meets any age restrictions and has no FDA‑labeled contraindications or labeled limitations of use. An FDA‑labeled contraindication or limitation of use excludes coverage. If product label or guidelines require specialist prescriber, documentation of specialist involvement or consultation should be provided to avoid denial.

    • Confirm age eligibility per product labeling
    • If FDA‑labeled contraindication exists, coverage excluded
    • Specialist prescriber documentation when required
    Documentation Required

    Provider documentation checklist — required tests & attestations

    Documentation requirements for specialty products (general examples): Submit diagnosis confirmation, relevant laboratory or diagnostic testing (e.g., genetic testing for targeted oncology agents, cardiac biopsy or 99mTc‑PYP imaging for ATTR‑CM, right heart catheterization for PAH agents, pulmonary function and HRCT for IPF), pre‑treatment labs (e.g., eosinophils for Nucala, hemoglobin for ESAs), prior therapy trials or contraindications, and prescriber attestation of education or technique when required (e.g., Inbrija inhaler education). For some products (e.g., Cayston) documentation must show presence of Pseudomonas aeruginosa. Where no documentation is specified, indicate 'no documentation requirements specified' in request.

    • Oncology/targeted agents: provide genetic testing when required
    • ATTR‑CM: biopsy or nuclear imaging + lab exclusion of AL amyloidosis
    • PAH agents: right heart cath hemodynamics required
    • IPF/ILD: HRCT pattern, PFTs (FVC, DLCO) and imaging per policy
    • ESA: hemoglobin documentation
    • Cayston: documentation of Pseudomonas aeruginosa
    Note

    Product‑specific exclusions and special handling (examples)

    Product‑specific exclusions and single‑use notes: VOWST limited to treatment of recurrent CDI per policy (not for primary CDI), requires definition of recurrent CDI (three or more prior episodes treated with antibiotics) and completion of bowel‑prep/magnesium citrate timing; Tolvaptan excludes concurrent use with Samsca and stage 5 CKD; Trikafta and other CFTR modulators cannot be used concurrently with other CFTR modulators. For certain medications (e.g., ADEM PAS, sodium oxybate, others where noted) check for specified drug interaction or concurrent therapy exclusions.

    • VOWST: single treatment course; recurrent CDI definition and bowel prep documentation required
    • Tolvaptan: exclude concurrent Samsca and stage 5 CKD
    • CFTR modulators: do not combine with other CFTR modulators
    Note

    Index‑only / no PA specified — operational note

    Index‑only / no PA entries: Some index entries are informational only and have no PA rules or denial triggers defined. When a product appears only in the index without accompanying PA criteria, treat as having no authorization/denial criteria specified and refer to formulary/admin guidance.

    • This section contains index entries only — no PA criteria provided
    • If no PA rules present, follow standard formulary request procedures

    Quantity, Duration and Refill Limits

    GATTEX quantity limit
    GATTEX dosing limitDose limited to FDA-approved 0.05 mg/kg/day
    Initial coverage duration3 months initial, then 12 months if renewal criteria met
    Indication requirementShort bowel syndrome with ≥1 year dependence on parenteral nutrition and inability to taper
    insulin administration supplies — 12 months supply
    Supply limitInsulin administration supplies covered as a 12 months supply
    Coverage conditionOnly covered under Part D when used concurrently with insulin
    ExamplesIncludes alcohol pads, pen needles, gauze, syringes, pen needles listed in policy
    JAYPIRCA — 6 months authorization
    Authorization durationInitial coverage duration: 6 months
    Prerequisite therapyFor CLL/SLL: ≥2 prior therapies including a BTK inhibitor and a BCL-2 inhibitor; for MCL: ≥2 prior systemic therapies including a BTK inhibitor
    Dose restrictionsLimited to a dose within FDA-labeled dosing guidelines
    KALYDECO — 12 months authorization
    Authorization durationCoverage duration: 12 months
    Mutation requirementPatient must have at least one CFTR mutation responsive based on in vitro assay data; patient must not be homozygous for F508del
    Concurrent therapy exclusionMay not be used concurrently with another CFTR modulator for the requested indication
    linezolid — 3 months authorization
    Authorization durationCoverage duration: 3 months
    Indication specificsCovered for VRE, susceptible pneumonia, or skin/soft tissue infections when prior therapy failure/contraindication documented
    Dose restrictionLimited to FDA-labeled dosing guidelines
    mifepristone 300 mg — dosing limited to FDA labeled dosing
    Dosing restrictionLimited to a dose within FDA-labeled dosing guidelines
    Indication exampleFor endogenous Cushing's disease: type 2 diabetes or glucose intolerance and failure or ineligibility for surgical resection
    Coverage durationInitial 6 months, then 12 months if renewal criteria met
    nitazoxanide — dosing limited to FDA labeled dosing
    Dosing restrictionLimited to a dose within FDA-labeled dosing guidelines
    Age restrictionIndication (Giardia/Cryptosporidium): patients age 12 and older
    Coverage duration10 days (per indication)
    Valchlor quantity limit (duplicate)
    Quantity limitApprovals limited to two 60 gram tubes per month
    Initial coverage durationInitial 6 months, then 12 months if renewal criteria met
    Prerequisite therapyPatient must have received at least one prior skin-directed therapy (e.g., topical corticosteroids, bexarotene gel)
    VALCHLOR quantity limit
    Quantity limitApprovals limited to two 60 gram tubes per month
    Initial coverage durationInitial 6 months, then 12 months if renewal criteria met
    Prerequisite therapyAt least one prior skin-directed therapy required before approval
    VOWST — 1 course
    Course limitLimited to a single treatment course (1 course)
    Treatment timing requirementsPatient must have completed antibiotic therapy 2–4 days prior and completed magnesium citrate bowel prep the day before and at least 8 hours prior to initiating VOWST
    Duration10 days per treatment course
    XIFAXAN (IBS-D) dosing
    IBS-D dosing550 mg three times daily for 14 days (retreatment limited to maximum two 14-day treatments for responders)
    Indication-specific limitsDifferent durations apply per indication (hepatic encephalopathy 12 months; travelers' diarrhea 3 days)
    Retreatment restrictionRetreatment for IBS-D limited to max two 14-day courses for responders

    Where Therapy is Administered / Coverage Setting

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Biosimilar Preferences and Requirements

    Note

    Clinical Thresholds and Key Numeric Criteria

    Hemoglobin thresholds for ESAs
    Adult CKD ESA thresholdHemoglobin < 10 g/dL (adults with CKD not on dialysis)
    Pediatric CKD threshold guidancePediatric CKD: hemoglobin approaches or exceeds 12 g/dL — guide dose reduction/interruption to decrease transfusions
    Cancer/chemotherapy contextHemoglobin thresholds aligned with avoiding RBC transfusion per indication
    Alpha-1 antitrypsin level
    Pretreatment AAT levelSerum alpha-1 antitrypsin (AAT) level < 11 micromoles/L
    Equivalent unitsOr <80 mg/dL by radial immunodiffusion or <57 mg/dL by nephelometry
    Clinical requirementPlus clinically evident emphysema and continuation of conventional emphysema treatments
    Pulmonary hemodynamics for PAH
    mPAP thresholdMean pulmonary artery pressure (mPAP) ≥ 20 mmHg
    PCWP thresholdPulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg
    PVR thresholdPulmonary vascular resistance (PVR) > 2 Wood units (some entries use ≥3 Wood units for certain agents)
    99mTc-PYP heart-to-contralateral ratio
    99mTc-PYP ratio thresholdHeart-to-contralateral ratio > 1.5 on 99mTc-PYP imaging
    Visual grade criterionOr visual grade ≥2 myocardial uptake on 99mTc-PYP
    Use contextRequired as part of noninvasive diagnostic criteria to confirm ATTR-CM (with absence of monoclonal protein)
    NYHA class
    NYHA classes allowedNYHA class I, II, or III (patient must be in NYHA I–III for ATTR-CM therapy)
    Documentation requirementNYHA class documented as part of ATTR-CM initial and renewal criteria
    Renewal considerationRenewal requires patient continues to have NYHA I–III and positive response
    Mean pulmonary artery pressure (mPAP)
    mPAP threshold (PAH entries)>= 20 mmHg
    ContextRequired on right heart catheterization to confirm Group 1 PAH for agents like bosentan and OPSUMIT
    Associated thresholdsUsed together with PCWP <=15 mmHg and elevated PVR
    Pulmonary capillary wedge pressure (PCWP)
    PCWP threshold<= 15 mmHg
    UseRequired on right heart catheterization to confirm Group 1 PAH
    Combined criteriaInterpreted with mPAP >=20 mmHg and elevated PVR
    Pulmonary vascular resistance (PVR)
    PVR threshold> 2 Wood units (policy entries often reference >2 WU; some PAH entries use ≥3 WU)
    ContextMeasured on right heart catheterization for PAH confirmation
    Agent-specific noteCertain product entries state PVR ≥3 Wood units for eligibility (see specific drug criteria)
    Liver enzyme limits for bosentan
    ALT/AST limitALT/AST ≤ 3× ULN (must not exceed) for bosentan initiation/continuation
    Bilirubin limitNo increase in bilirubin ≥2× ULN
    ContextLiver enzyme and bilirubin limits are required for bosentan eligibility
    Liver iron concentration (LIC)
    LIC threshold>= 5 mg Fe per gram dry weight (liver iron concentration) for non-transfusion-dependent thalassemia indication
    Associated ferritinRequires serum ferritin >300 mcg/L for non-transfusion-dependent cases
    PrescriberPrescribed by or in consultation with hematologist/oncologist
    Serum ferritin (non-transfusion-dependent)
    Non-transfusion ferritin> 300 mcg/L for chronic iron overload due to non-transfusion-dependent thalassemia
    Transfusion-related ferritin> 1000 mcg/L for transfusion-related chronic iron overload
    ContextUsed as part of deferasirox initial authorization criteria
    Serum ferritin (transfusion-related)
    Transfusion-related ferritin threshold> 1000 mcg/L for transfusion-related chronic iron overload (deferasirox)
    LIC requirementAlso requires LIC >=5 mg Fe/g dry weight for certain non-transfusion indications
    PrescriberHematologist/oncologist involvement expected
    Eosinophil count (Dupixent)
    Eosinophil threshold (Dupixent/Nucala)>= 150 cells/µL within prior 12 months (pre-treatment)
    Use caseRequired for severe eosinophilic asthma eligibility for agents like Nucala and referenced in Dupixent criteria
    DocumentationPretreatment eosinophil count must be documented within the past 12 months
    Pre-treatment eosinophil threshold
    Pre-treatment eosinophil threshold>= 150 cells/µL (within prior 12 months) required for severe eosinophilic asthma agents
    Renewal requirementContinued specialist prescribing and evidence of positive response for renewal
    ContextApplied to Nucala and similar eosinophil-targeted biologics
    Ofev pulmonary function thresholds
    Ofev FVC threshold (IPF)Baseline FVC >= 50% predicted
    Ofev %DLCO thresholdBaseline %DLCO >= 30% predicted
    Progressive ILD criteriaFor progressive fibrosing ILD: FVC >=45% with >10% fibrosis on HRCT and decline criteria as specified
    Severe primary IGF-1 deficiency thresholds
    Severe primary IGF-1 deficiency thresholdsHeight SDS <= -3.0 and basal IGF-1 SDS <= -3.0
    DocumentationPrescribed by or in consultation with an endocrinologist; renewal requires positive response
    ContextApplies to IGF-1 therapy eligibility for growth failure
    Mean pulmonary artery pressure (mPAP) (duplicate)
    mPAP repeated threshold>= 20 mmHg (documented on right heart catheterization)
    PCWP repeated threshold<= 15 mmHg
    PVR repeated threshold> 2 Wood units
    PCWP (duplicate)
    PCWP repeated<= 15 mmHg (documented on right heart catheterization)
    UseRequired for confirming Group 1 PAH across several product entries
    Associated metricsConsidered with mPAP >=20 mmHg and PVR >2 Wood units
    PVR (duplicate)
    PVR repeated> 2 Wood units (documented on right heart catheterization)
    NoteSome entries specify ≥3 Wood units for certain agents (see agent-specific criteria)
    ContextPart of hemodynamic criteria to diagnose PAH
    Forced Vital Capacity (FVC)
    FVC threshold>= 50% predicted (baseline) for IPF eligibility
    ContextRequired for pirfenidone and Ofev eligibility in IPF; must exclude other ILD causes
    RenewalRenewal requires follow-up visit and evidence of positive response
    DLCO (% predicted)
    DLCO threshold>= 30% predicted (%DLCO) for IPF and other indications
    ContextUsed with baseline FVC and HRCT/histopathology to establish eligibility for antifibrotic therapy
    Progressive ILD note%DLCO thresholds apply for progressive phenotypes per product-specific rules
    LDL threshold for PCSK9 inhibition consideration
    LDL threshold for PCSK9 consideration> 70 mg/dL after trial of high-intensity statin plus ezetimibe (or documented statin intolerance)
    Prior therapy requirementTrial of high-intensity statin + ezetimibe concomitantly for specified minimum weeks (documented)
    PrescriberPrescribed by or in consultation with cardiologist/endocrinologist or lipid specialist
    LDL threshold for ASCVD/HeFH
    LDL threshold for ASCVD/HeFHLDL remains above 70 mg/dL despite lipid-lowering therapy
    Step therapy alternativeOr documented statin intolerance per policy definition
    DocumentationDuration of statin/ezetimibe trial should be documented; weeks value per source
    REZDIFFRA fibrosis stage requirement
    Fibrosis stage requirementStage F2 or F3 fibrosis required for REZDIFFRA initial approval
    Renewal constraintMust not have progressed to stage F4 (cirrhosis) for renewal
    Diagnostic confirmationDiagnosis confirmed by liver biopsy or elastography/imaging as specified
    PAH hemodynamic thresholds
    PAH hemodynamic thresholds (entry)Mean PAP ≥20 mmHg; PCWP ≤15 mmHg; PVR ≥3 Wood units (one entry) or >2 Wood units (other entries)
    Agent-specific noteSome agent criteria require PVR ≥3 WU (e.g., tadalafil PAH entry) while others use >2 WU
    PrescriberPrescribed by or in consultation with cardiologist or pulmonologist
    Opioid tolerance thresholds
    Opioid tolerance examplesExamples: ≥60 mg oral morphine/day; ≥25 mcg/hr transdermal fentanyl; ≥30 mg oral oxycodone/day; ≥60 mg oral hydrocodone/day
    Use caseRequired for fentanyl buccal lozenge on a handle eligibility for breakthrough cancer pain
    DocumentationAround-the-clock opioid therapy history (≥1 week) must be documented
    Ejection fraction
    Ejection fraction thresholdEjection fraction < 45% required for VERQUVO initial eligibility
    Associated criteriaPlus additional HF severity criteria (prior HF hospitalization or recent outpatient IV diuretic) and inadequate response to guideline therapies
    PrescriberPrescribed by or in consultation with a cardiologist
    Mean pulmonary artery pressure (mPAP) (another entry)
    mPAP repeated entry>= 20 mmHg (documented on right heart catheterization)
    ContextUsed across multiple PAH product entries to confirm diagnosis
    Combined useInterpreted with PCWP <=15 mmHg and PVR >2 Wood units
    PCWP (another entry)
    PCWP repeated entry<= 15 mmHg (documented on right heart catheterization)
    UseRequired for Group 1 PAH confirmation across product criteria
    NoteValues consistent with other PAH threshold entries
    PVR (another entry)
    PVR repeated entry> 2 Wood units (documented on right heart catheterization)
    Agent variationSome entries specify ≥3 Wood units for particular agents; check product-specific criteria
    ContextPart of standard hemodynamic confirmation for PAH
    Baseline IgE serum level (XOLAIR)
    Baseline IgE requirement (XOLAIR)>= 30 IU/mL (baseline serum IgE) for IgE-mediated severe asthma or food allergy criteria
    Allergen testingPositive skin prick or blood test to a perennial aeroallergen required for severe asthma entry
    Specialist prescriberPrescribed by or in consultation with asthma specialist/allergist/pulmonologist/immunologist
    Baseline IgE (duplicate)
    Baseline IgE duplicate>= 30 IU/mL (baseline) — repeated entry for XOLAIR criteria
    Indication contextsUsed for severe asthma and IgE-mediated food allergy eligibility per policy
    DocumentationBaseline IgE and allergen testing results must be provided when required
    Castration-level testosterone
    Castration-level testosteroneTestosterone < 50 ng/dL required (castrate level) for XTANDI initial/renewal criteria
    Alternate documentationOr documentation of bilateral orchiectomy or concurrent GnRH analog use
    Coverage durationSix months per initial XTANDI entry

    Policy Background

    This policy excerpt summarizes Medicare Part D prior authorization standards for selected specialty and pharmacy drugs: coverage generally requires documentation of an FDA‑approved diagnosis (or acceptable diagnostic confirmation), evidence of prior trial(s) or contraindication to preferred alternatives when specified, absence of FDA‑labeled contraindications, and dosing limited to FDA‑labeled guidelines. Many biologic agents require specialist prescribing or consultation, and typical initial coverage durations are 6 to 12 months depending on the product; renewals commonly require evidence of clinical benefit and a recent prescriber visit.